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Renal calcified lesions are known as one of the complications during 
adrenocorticotropic hormone (ACTH) therapy for intractable epilepsy. However, 
laboratory changes during the therapy or laboratory features of high-risk cases with 
renal calcified lesions are yet to be clarified. 
Methods 
In this study, 43 patients with West syndrome ≤2 years were included. We 
retrospectively reviewed age and body mass index at the beginning of ACTH therapy, 
as well as the amount of fluid intake, daily urinary volume, and laboratory data during 
therapy. In addition, we studied the urinary sediment of the cases with renal calcified 
lesions diagnosed by computed tomography. 
Results 
After initiating ACTH treatment, urinary calcium (Ca)/creatinine ratio and urinary pH 
increased within 2 weeks. Urinary crystals and renal tubular epithelial cells (RTECs) in 
urinary sediment were frequently found in most cases. Urinary Ca levels, proteinuria or 
frequency of urinary crystals, and number of RTECs in the urinary sediment were 
significantly higher in patients with epithelial casts (ECs) or hematuria than in patients 
without these findings. Among the 7 patients who underwent abdominal CT, ECs or 
hematuria were found only those with renal calcified lesions. These findings suggested 
that patients with ECs or hematuria were more likely to have calcified lesions. 
Conclusions 
The risk of renal calcified lesions increases after 2 weeks of ACTH treatment. 
Abnormal findings in urinary sediments might be an early sign of renal calcification 
during ACTH therapy. 
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Renal calcified lesions composed of calcium (Ca) and phosphate (P) can occur 
especially when zonisamide (ZNS) or topiramate (TPM) are combined with 
adrenocorticotropic hormone (ACTH) therapy for the treatment of intractable epilepsy 
[1, 2]. However, there have been few reports on the changes in laboratory parameters 
relating to renal calcified lesions or laboratory features of patients with renal calcified 
lesions when treated with ACTH therapy alone [3]. 
An ultrasonography is often used when diagnosing renal calcified lesions; 
however, its sensitivity is insufficient [4]. Furthermore, infants with renal calcified 
lesions are often asymptomatic. To improve detection of patients with renal calcified 
lesions, simple and easy-to-use examinations are required.  
Most renal calcified lesions are formed from deposition of crystals in the renal 
tubules [5]. During this process, changes in urinary sediment can be found [6, 7]. 
Although urinary sediment can be useful according to these facts, no studies have 
examined about urinary sediment during ACTH therapy in patients with renal calcified 
lesions. 
Therefore, this study aimed to evaluate changes in laboratory values that are 
related to the development of renal calcified lesions during ACTH therapy without ZNS 




We retrospectively reviewed pediatric patients aged ≤2 years treated with ACTH 
therapy for West syndrome in Okayama University Hospital from January 2010 to 
December 2017. Patients who had premature discontinuation of ACTH therapy, those 
with calcified lesions or nephritis before ACTH therapy, and those with congenital 
diseases that can cause renal calcified lesions such as cystinuria, were excluded. Finally, 
43 patients were included in this study. Synthetic ACTH administration was conducted 
intramuscularly once a day at a dose of 0.005 or 0.025 mg/kg/day. Dose of ACTH 
administration was decided depending on the severity and reactivity to treatment. Daily 
ACTH therapy was completed when the effect of the therapy for each patient reached a 
plateau. In the following week of treatment, we administered ACTH on alternating 
days. In our hospital, we administer ACTH daily for 4 weeks and on alternating days for 
1 week for most of the cases. During therapy, we obtained blood and urinary samples 
twice a week for most of the patients. We randomly examined the urine during daytime 
and used a urine bag to obtain urine because all patients were aged ≤2 years in this 
study. Brain magnetic resonance imaging (MRI) or computed tomography (CT) were 
performed for all patients to evaluate brain shrinkage after the treatment. 
Sex, age, and standard deviation (SD) score of body mass index (BMI) 
calculated by using “Excel-based Clinical Tools for Growth Evaluation of Children” 
made by The Japanese Society for Pediatric Endocrinology (taikakushisu_v3.3.xlsx, 
version 3.3 http://jspe.umin.jp/medical/chart_dl.html), were recorded at the beginning of 
ACTH therapy. We also collected data on the amount of fluid intake, daily urinary 
volume, and laboratory data before and during therapy. Laboratory data included 
calcium and phosphate levels in serum and urine, urinary Ca/creatinine (Ca/Cr) ratio, 
urinary P/creatinine (P/Cr) ratio, urinary pH, renal tubular reabsorption rate of Ca and P 
(%TRCa and %TRP, respectively), and urinary sediment and quantitative test of urine. 
We examined laboratory data that were measured within one month before ACTH 
therapy and during the therapy. We examined sequential findings on the urinary 
sediment during therapy in 7 patients who underwent abdominal CT examination. We 
also examined the side effects of ACTH therapy, including irritation, hypokalemia, 
hypertension, brain shrinkage, and epithelial casts (ECs) or hematuria in urinary 
sediment, in addition to renal calcified lesions. 
Although nephrocalcinosis (NC), nephrolithiasis (NL), and urolithiasis (UL) 
develop due to a common cause and often coexist, we defined NL and UL as a solid 
stone appearing in the kidneys and urinary tracts, respectively, and we defined NC as 
small deposits of calcification in the renal parenchyma. We defined calcified lesions as 
including NL, UL, and NC. Abdominal CT was performed for 7 patients within 50 days 
after ACTH therapy. The decision to perform abdominal CT is depending on each 
physician’s discretion. 
Regarding the urinary sediment, we adopted the guideline of the Japanese 
Committee for Clinical Laboratory Standards (https://doi.org/10.14932/jamt.17J1-1e). 
Hematuria and renal tubular epithelial cells (RTECs) were defined as ≥5 red blood cells 
and ≥1 RTECs per high-power field (HPF) (400× magnification), respectively. In this 
study, we discriminate ECs from RTECs; we defined ECs as casts composed by RTECs 
and RTECs as scattered epithelial cells from renal tubules. 
 Hypertension was diagnosed when systolic or diastolic blood pressure 
increased above 95th percentile for age; we diagnosed as hypertention when systolic 
blood pressure reached ≥105 mmHg, or diastolic blood pressure reached ≥70 mmHg 
[8], or antihypertensive drug treatment. 
Regarding the efficacy of the ACTH therapy, we judged the treatment as 
effective when epileptic seizures disappeared. We also examined the duration from the 
start of treatment to the onset of effects. 
 
Statistical analysis 
 Numerical variables were compared using the Mann–Whitney U-test, whereas 
the categorical variables were compared using Fisher’s exact test in this study. 
Laboratory data are reported as mean ± standard error. Multivariate analysis was not 
performed because of the small sample size. We defined P<0.05 as statistically 
significant. We used R commander (version 2.3–0) based on R (version 3.3.2, 
http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/ statmed.html). This study was 
approved by the Medicine Ethics Committee of Okayama University Hospital. All 
patients and/or their parents were informed about the study and given the option to 
refuse participation in this study. 
 
Results 
Laboratory data during ACTH therapy (Figure 1) 
 In our study, average duration of ACTH therapy was 34 days. Fluid intake and 
urinary volume increased after initiating therapy (Figure 1a, b). Serum Ca levels did not 
change during therapy (Figure 1c). After initiating ACTH therapy, urinary Ca level and 
Ca/Cr ratio were transiently decreased. After 2 weeks of treatment, although the urinary 
Ca level remained at the similar levels (Figure 1d), the Ca/Cr ratio in urine increased 
(Figure 1e), compared to the values before therapy. %TRCa gradually decreased within 
2 weeks of treatment (Figure 1f). P levels in serum and urine decreased shortly after 
initiating treatment (Figure 1g, h). During treatment, %TRP decreased and urinary P/Cr 
ratio increased (Figure 1i, j). Urinary pH gradually increased after initiating ACTH 
therapy. The mean urinary pH increased to approximately 7.5 at one week after starting 
therapy and was maintained thereafter (Figure 1k). 
 As shown in Table 1, before ACTH therapy, there were no findings in the 
urinary sediment in most of the patients. In contrast, changes in urinary sediment were 
found in 40 (93%) patients during the therapy. ECs or hematuria was found in 13 
patients and urinary crystals or RTECs preceded these findings.  
Among the 7 patients who underwent abdominal CT, 4 had renal calcified 
lesions after therapy. All of the 4 patients had NC or NL and 2 had UL. Figure 2 shows 
the sequential findings in the urinary sediment in these 7 patients. Renal calcified 
lesions were found in cases 1 to 4, but none were found in cases 5 to 7. In cases 1 to 4, 
ECs or hematuria preceded by crystals or RTECs were found. In the other 3 cases 
without renal calcified lesions, only the crystals or RTECs were found (Figure 2).  
 
Clinical features of patients with ECs or hematuria (Table 2) 
Given that ECs or hematuria were considered important after comparing the 
findings of 7 patients who underwent abdominal CT examination, all 43 patients were 
divided into the following 2 groups according to their urinary findings: patients with 
ECs or hematuria (group 1) during ACTH therapy and those without such finding 
(group 2). Groups 1 and 2 comprised 13 and 30 patients, respectively. In group 1, ECs 
and hematuria were found in 12 and 2 cases, respectively. The median of mean ECs of 
each case was 9 (1-27)/whole field. The mean red blood cell count of the 2 cases was 15 
and 46/HPF, respectively. There were no differences in age and SD score of BMI when 
the treatment was initiated, and in the frequency of laboratory examinations between the 
groups. We found that urinary Ca levels, proteinuria, frequency of urinary crystals, and 
number of RTECs in the urinary sediment were significantly different between the 2 
groups, as group 1 showed higher urinary Ca levels, tended to show proteinuria, and had 
higher frequency of urinary crystals RTECs >4/HPF. The urinary Ca/Cr ratio was not 
significantly different between the 2 groups. 
 
Duration from the start of treatment to the onset of effects and association between 
treatment effects and side effects 
 In our study, epileptic seizures were completely suppressed in 37 cases and we 
judged that ACTH therapy was effective in these cases. In 4 cases, epileptic seizures 
were not completely suppressed, whereas in the other 2 cases, clinical manifestation of 
epileptic seizures was not obvious and we could not evaluate the efficacy of ACTH 
therapy. In our study, the mean duration from the start of treatment to seizure 
suppression for the 37 cases was 10 days. We compared the frequency of the side 
effects between the group effectively treated with ACTH therapy and the group whose 
epileptic seizures were not effectively treated with ACTH therapy (Table 3). All cases 
had brain shrinkage, except for 1 case with severe brain atrophy before the therapy. 
Hypertension was also found in most of the cases. The ACTH therapy was effective for 
all 7 patients who underwent abdominal CT examination. 
 
Discussion 
We found remarkable changes in the urinary Ca and P levels within 2 weeks 
after initiating ACTH therapy. ACTH stimulates parathormone (PTH) as well as 
cortisol [3, 9]. Cortisol can increase urinary Ca/Cr and P/Cr ratio by decreasing %TRCa 
and %TRP. PTH reduces urinary Ca/Cr ratio and increases urinary P/Cr ratio by 
increasing %TRCa and decreasing %TRP [3, 9]. From these facts, our data imply that 
PTH mainly causes the urinary changes in Ca or P in the first several days after 
initiating ACTH therapy, and the influence of cortisol becomes apparent after 2 weeks 
of treatment. Furthermore, urinary dilution by the increased fluid intake also affects the 
urinary data, and urinary Ca and P levels were not increased during the therapy 
compared to their values before treatment.  
Although the effect of ACTH on urinary pH has not been previously reported, 
urinary pH gradually increased up to approximately 7.5 within one week of therapy in 
our study. Previously, patients treated with ZNS or TPM combined with ACTH therapy 
had alkaline urine because of the carbonic anhydrase effect of ZNS or TPM [1, 2, 10]. 
However, we did not use these drugs during ACTH therapy. ACTH can affect urinary 
pH by various mechanisms. Besides cortisol, aldosterone secretion is also stimulated by 
ACTH [11], and these hormones can increase the urinary pH [12-14]. Given that the 
urinary pH after meals increases [6], the increased appetite during ACTH therapy is one 
of these mechanisms. Hyperventilation caused by mood disturbance during treatment 
can also cause urine alkalinity [15]. 
 Although 93% of the patients had no findings in the urinary sediment before 
ACTH therapy in our study, urinary crystals or RTECs were frequently found in most of 
the patients during therapy. Renal tubular injury by crystals is suspected to have caused 
these findings in the urinary sediment [6, 7] Furthermore, our findings of ECs or 
hematuria in some of the patients are consistent with the findings of renal tubular injury 
caused by calcified lesions or its precursor lesions [6, 7]. In the patients who underwent 
CT, ECs or hematuria preceded by urinary crystals or RTECs were found only in 
patients with calcified lesions. Sequential changes in the urinary sediment from crystals 
or RTECs to ECs or hematuria may reflect the process of calcified lesion formation. 
This process involves a transition from Randall’s plugs to calcified lesions by 
substituting the epithelial cells of the renal tubule [5-7]. Our data suggest that calcified 
lesions should be suspected in patients especially with ECs or hematuria during ACTH 
therapy. ECs or hematuria, in addition to other side effects, were not associated with the 
effectivity of the treatment in our study. 
 We found that Ca concentrations in the urine during ACTH therapy were 
significantly higher in the cases with ECs or hematuria than in the cases without these 
findings. Although urinary Ca/Cr ratio is thought to be important when evaluating the 
risk of Ca-related stones [16], this parameter was not significantly different between the 
2 groups in our study. Generally, crystals are formed when the solubility of salts 
exceeds a threshold, and pH or salt concentrations have a significant influence on this 
threshold [6, 17]. This indicates the importance of urinary Ca concentrations in the 
formation of calcified lesions. However, we believe that urinary Ca/Cr ratio is also 
important, because urinary Ca/Cr ratio indicates daily Ca excretion [18, 19]. Adequate 
fluid intake is required for both patients with high urinary Ca levels and those with high 
urinary Ca/Cr ratio to prevent calcified lesion formation. Except for urinary Ca 
concentrations, proteinuria, frequency of urinary crystals, and the number of RTECs in 
the urinary sediment were different between the 2 groups. Frequent urinary crystals 
suggest calcified lesions, whereas occasional urinary crystals can be found in normal 
infants [20]. The presence of many RTECs in the urinary sediment indicates a high 
disturbance of the renal tubules [6, 7]. Previous reports showed that increased albumin 
concentrations contribute to cast formation [6], and proteinuria was frequently found in 
patients with calcified lesions [21]. These findings are consistent with our results. We 
speculate that patients with calcified lesions caused by ACTH therapy tend to show 
frequent crystalluria, proteinuria, or many RTECs in the urinary sediment besides ECs 
or hematuria. Therefore, physicians need to pay attention to calcified lesions in patients 
with these findings during ACTH therapy. 
 This study had some limitations. First, the urinary samples were obtained 
randomly because this was a retrospective study, despite the fact that urinary sampling 
in the fasting state is recommended for evaluating urinary Ca. However, we frequently 
obtained urinary samples for every patient and in the same timeframe. Second, the 
underlying causes of West syndrome varied, which can influence the outcomes of this 
study. Third, because we did not perform abdominal CT in all of the patients, we could 
not diagnose the calcified lesions, except for 4 patients. Therefore, we could not 
precisely show the relationship between calcified lesions and ECs or hematuria in a 
large number of patients. Fourth, although we examined a large number of patients 
compared with a previous study [3], the number of patients especially with ECs or 
hematuria was insufficient. Fifth, because ECs or hematuria in the urinary sediment is 
not frequently found, some cases may not be detected. However, the possible utility of 
urinalysis to detect high-risk patients with calcified lesions during ACTH therapy was 
demonstrated in this study. 
 In conclusion, within 2 weeks after initiating ACTH therapy, urinary pH and 
Ca/Cr ratio increased and crystals can be easily formed. Detecting urinary sediments is 
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Table 1. Findings in the urinary sediment before and during the therapy 
 
   Before (%) During (%) 
No finding 40 (93) 3 (7) 
Urinary crystal 3 (7) 39 (91) 
RTECs 0 (0) 33 (77) 
ECs 0 (0) 12 (28) 
Hematuria 0 (0) 2 (5) 





Table 2. Differences in clinical characteristic between patients with (group 1) and without ECs or hematuria (group 2) 
 
Parameter Group 1 (n=13) Group 2 (n=30) P-value 
Median (min-max) or n 
(%) 
Median (min-max) or n 
(%) 
Age (months) 7 (5-23) 8 (3-24) 0.18 
Sex, male (%) 7 (53) 16 (53) 1.0† 
SD score of BMI -0.28 (-2.5-1.2) -0.02 (-2.2-2.4) 0.34 
Frequency of urinalysis during treatment 10 (8-13) 10 (6-12) 0.19 
Mean serum Ca during treatment (mg/dL) 9.8 (8.5-10.1) 9.7 (8.9-10.6) 0.6 
Mean serum P during treatment (mg/dL) 3.7 (3.1-4.6) 4.1 (3.0-5.4) 0.14 
Mean urinary Ca during treatment (mg/dL) 8.7 (5.4-16.5) 6.2 (3.1-11.1) 0.013* 
Mean urinary Ca/Cr ratio during treatment (mg/dL) 0.6 (0.3-10.0) 0.6 (0.3-15.0) 0.63 
Mean urinary P during treatment (mg/dL) 20.7 (8.1-46.7) 16.8 (9.1-68) 0.27 
Mean urinary pH during treatment 7.4 (6.9-7.8) 7.5 (6.7-7.7) 1.0 
Proteinuria during treatment (%) 9 (69) 7 (23) 0.007†* 
Glucosuria during treatment (%) 5 (39) 15 (50) 0.53† 
Pyuria during treatment (%) 8 (62) 12 (40) 0.32† 
Frequency of crystals in urinary sediment during treatment 4 (2-8) 2 (0-8) 0.038* 
Frequency of RTECs in urinary sediment during treatment    
1-4/HPF 1 (0-4) 1 (0-6) 0.54 
5-9/HPF 1 (0-3) 0 (0-2) 0.028* 
*P < 0.050. 
†P values are for the Fisher’s exact test. 
P values are for Mann–Whitney U-test unless otherwise indicated. 






10-19/HPF 1 (0-3) 0 (0-1) 0.001* 
Table 3. Relation between complication and effectivity of ACTH administration 
 
Complication n (%) 
Hematuria or ECs 
in urinary sediment 
Irritation Hypokalemia Hypertension Brain shrinkage 
Effective group (n=37) 12 (32) 34 (92) 28 (76) 36 (97) 36 (97) 
Non-effective group 
(n=4) 
1 (25) 4 (100) 4 (100) 4 (100) 4 (100) 
P-value 1.0 0.25 0.56 1.0 1.0 
P-values are for the Fisher’s exact test. 




Changes in fluid intake, urinary volume, and laboratory data, including Ca and P levels, 
before and during the 30-day treatment. All data are shown as mean ± standard error, 
and the minimum to maximum numbers of cases are also shown.  
 
Fig. 2 
Findings in the urinary sediment during ACTH therapy in patients with or without renal 
calcified lesions as diagnosed by abdominal CT. Cases 1 to 4 were diagnosed as having 
calcified lesions, whereas cases 5, 6, and 7 did not have calcified lesions. Cases 1 to 4 
and cases 5 to 7 were separated by a dotted line. 
